Project Grant R03AG103687
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $156K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, DC 20057, USA
Similar Awards
- The National Institute on Aging awarded New York University $642,063 under the Aging Research program (CFDA 93.866) on January 15, 2026, to investigate gabaergic circuit targets for modulating entorhinal cortex and hippocampal dynamics in Alzheimer's disease. The research examines vasoactive intestinal peptide and cholecystokinin inhibitory neuron microcircuits within hippocampal area CA1, with the hypothesis that modulating activity in these circuits can improve lateral entorhinal cortex–CA1...
- The National Institute on Aging awarded Temple University $132,448 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate NMDAR/TRPM4 signaling and mitochondrial dysfunction in Alzheimer's disease. The project tests the functional coupling of N-methyl-D-aspartate receptors (NMDARs) and TRPM4 channels as a central mechanism of neurotoxicity in Alzheimer's disease and related dementias. Research employs induced pluripotent stem cell organoids carrying AD-causing...
- The National Institute on Aging awarded $427,625 to The Washington University on September 1, 2026, under the Aging Research program (CFDA 93.866) to probe cerebellar cortex computations in Alzheimer's disease. The work examines cerebellar nodulus and uvula function in two Alzheimer's disease mouse models—APP/PS1 and 3XTG-AD—at 3, 6, and 12 months of disease progression to assess how hallmarks of Alzheimer's disease contribute to cerebellar dysfunction. The project tests the hypothesis that...
- The National Institute on Aging awarded Emory University $643,613 on April 1, 2026, under the Aging Research program (CFDA 93.866) to discover glycosylation-based disease processes and identify glyco-biomarkers and targets for improving Alzheimer's disease diagnosis, prognosis, and intervention. The recipient will perform innovative research using an integrated platform of intact glycopeptide-based quantitative glycoproteomics and systems biology to elucidate brain glycoproteome alterations in...
- The National Institute on Aging awarded the University of Virginia $583,815 on August 15, 2026, under the Aging Research program (CFDA 93.866) to support research into oligodendrocyte lineage dysfunction during aging and Alzheimer's disease. The project aims to understand how myelin loss—a pathology common to both aging and Alzheimer's disease—develops in the central nervous system and to identify therapeutic targets for cognitive impairment. The research focuses on oligodendrocyte precursor...
- The National Institute on Aging awarded the University of Pittsburgh $664,619 on January 1, 2026, under the Aging Research program (CFDA 93.866) to develop multiscale computational and experimental models of neurometabolic coupling across age-related cognitive decline and late-onset Alzheimer's disease. The research integrates in vivo two-photon microscopy, multispectral wide-field imaging, and magnetic resonance imaging to characterize the relationship between neuronal activity and metabolic...
- The National Institute on Aging awarded Marquette University $309,000 on May 15, 2026, under the Aging Research program (CFDA 93.866) to conduct longitudinal imaging studies in a preclinical Alzheimer's disease model aimed at identifying early biomarkers of cognitive decline. The project uses in vivo calcium imaging of prefrontal cortical neuronal ensembles and two-photon imaging of amyloid-beta deposits in a transgenic rat model to track changes in genetically defined excitatory and...
- The National Institute on Aging awarded Purdue University $387,183 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop mass spectrometry-based proteomics strategies examining post-translational modifications related to protein aggregation and extracellular vesicle-mediated propagation in neurodegenerative disease, with emphasis on Alzheimer's disease. The recipient will establish a novel proteomics platform to profile N-terminal acetylation landscapes in primary...
- The National Institute on Aging awarded the University of Virginia $433,417 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of hippocampal perineuronal net complexity in Alzheimer's disease-associated social memory dysfunction. The research examines how disruptions in perineuronal nets—specialized extracellular matrix structures surrounding neurons in the hippocampal CA2 region—contribute to social memory deficits in Alzheimer's disease. The project...
- The National Institute on Aging awarded Rensselaer Polytechnic Institute $698,712 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate apolipoprotein E and reelin interactions in Alzheimer's disease pathology. The research tests the hypothesis that APOE E4 competes with reelin for receptor and heparan sulfate binding, thereby reducing protective reelin signaling and increasing Alzheimer's disease risk. Work includes mechanistic studies using split luciferase assays...